^(18)F-FDG PET-CT最大标准摄取值在弥漫大B细胞淋巴瘤患者预后评估中的价值  

Prognostic value of ^(18)F-FDG PET-CT maximum standardized uptake value in patients with diffuse large B-cell lymphoma

作　　者：王莉莉[1] 米彦霞[1] 王列样[2] Wang Lili;Mi Yanxia;Wang Lieyang(Department of Nuclear Medicine,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China;Department of Hematology,Shanxi Provincial Cancer Hospital,Taiyuan 030013,China)

机构地区：[1]山西省肿瘤医院核医学科,太原030013 [2]山西省肿瘤医院血液内科,太原030013

出　　处：《白血病．淋巴瘤》2020年第12期731-734,共4页Journal of Leukemia & Lymphoma

摘　　要：目的评价^(18)F-FDG PET-CT最大标准摄取值(SUVmax)在弥漫大B细胞淋巴瘤(DLBCL)患者预后评估中的价值。方法回顾性分析2002年1月至2018年12月山西省肿瘤医院诊断为DLBCL且治疗前接受^(18)F-FDG PET-CT检查的86例患者的临床资料和随访信息。通过受试者工作特征(ROC)曲线选取SUVmax最佳界值(10),将患者分为高SUVmax(≥10)组和低SUVmax(<10)组。采用Kaplan-Meier生存曲线分析SUVmax与总生存(OS)和无进展生存(PFS)时间之间的关系。通过单因素分析和多因素Cox比例风险模型评估SUVmax对DLBCL预后评估的意义。结果86例DLBCL患者中位OS时间53.3个月,3年OS率57.0%,3年PFS率53.5%。高SUVmax组3年OS率44.4%,3年PFS率42.2%;低SUVmax组3年OS率70.7%,3年PFS率65.9%,差异均具有统计学意义(均P<0.05)。单因素和多因素分析显示,SUVmax是影响DLBCL患者OS和PFS的独立预后因素(OS:HR=0.454,95%CI 0.251~0.823,P=0.009;PFS:HR=0.521,95%CI 0.292~0.930,P=0.027)。结论PET-CT SUVmax与DLBCL患者OS和PFS相关,可以预测DLBCL患者的预后。Objective To evaluate the prognostic value of ^(18)F-FDG PET-CT maximum standardized uptake value(SUVmax)in patients with diffuse large B-cell lymphoma(DLBCL).Methods The clinical data and follow-up information of 86 DLBCL patients who were diagnosed and received ^(18)F-FDG PET-CT before treatment in Shanxi Provincial Cancer Hospital from January 2002 to December 2018 were analyzed retrospectively.The receiver operating characteristic(ROC)curve was used to select the best cut-off value of SUVmax(10),and the patients were divided into high SUVmax(≥10)group and low SUVmax(<10)group.Kaplan-Meier survival curve was used to analyze the relationship of SUVmax with overall survival(OS)time and progression-free survival(PFS)time.The prognostic significance of SUVmax in patients with DLBCL was evaluated by univariate analysis and multivariate Cox proportional hazard model.Results The median OS time of 86 patients with DLBCL was 53.3 months,the 3-year OS rate was 57.0%,and the 3-year PFS rate was 53.5%.The 3-year OS rate in the high SUVmax group was 44.4%,and the 3-year PFS rate was 42.2%;the 3-year OS rate in the low SUVmax group was 70.7%,and the 3-year PFS rate was 65.9%;the differences were statistically significant(both P<0.05).Univariate and multivariate analyses showed that SUVmax was an independent prognostic factor for OS and PFS in patients with DLBCL(OS:HR=0.454,95%CI 0.251-0.823,P=0.009;PFS:HR=0.521,95%CI 0.292-0.930,P=0.027).Conclusion ^(18)F-FDG PET-CT SUVmax is associated with OS and PFS,and it can predict the prognosis of patients with DLBCL.

关 键 词：淋巴瘤 大B-细胞 弥漫性 正电子发射断层显像术 最大标准摄取值 预后 

分 类 号：R733.1[医药卫生—肿瘤]